艾美疫苗mRNARSV疫苗临床前试验显著成功
财中社2月5日电艾美疫苗（06660）发布公告，宣布其mRNARSV疫苗在临床前动物试验中表现出显著的免疫效果，特异性IgG抗体滴度、真病毒中和抗体效价及特异性T细胞免疫均高于国际上市对照疫苗。该疫苗已向美国食品和药品监督管理局(FDA)申报临床，标志着公司在疫苗研发方面的重大进展。
RSV是全球范围内常见的呼吸道感染病原体，接种疫苗是有效预防重症感染的手段。目前全球尚无获批的针对RSV的抗病毒特效药，2023年度RSV疫苗的全球销售额为24.6亿美元，预计到2030年市场规模将达到约167亿美元。公司在mRNA疫苗研发方面具有成熟的体系和自主专利，已建立符合GMP标准的生产车间，未来有望加快产品的商业化进程，为公司带来可观的业绩增长。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10